Gyre Therapeutics (GYRE)
A majority-owned Beijing unit sells China's pirfenidone lung-fibrosis therapy while San Diego runs the antifibrotic pipeline.
$7.34
vs last close−0.15 (−2.00%)
Something off on this page? Send us feedback.
Next report
Nov 6, 26
in 44 days
EPS estimate
−$0.15
Revenue estimate
$28.4M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$0.01$0.03$0.02$0.06−$0.02−$0.05−$0.12Pending
Estimate$0.04$0.03$0.03$0.05$0.06−$0.06−$0.06−$0.15
Surprise−75.0%0.0%−33.3%+20.0%−133.4%+16.7%−111.8%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$27.9M$22.1M$26.8M$30.6M$37.2M$22.5M$29.1MPending
Estimate$23.5M$28.4M$30.8M$32.9M$35.4M$31.6M$26.5M$28.4M
Surprise+18.6%−22.3%−13.1%−7.2%+5.0%−28.8%+9.9%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2026 | −$0.12 | — | — |
| Nov 2026 | −$0.15 | — | — |
| Aug 2026 | −$0.06 | −$0.12 | −111.8% |
| May 2026 | −$0.06 | −$0.05 | +16.7% |
| Mar 2026 | $0.06 | −$0.02 | −133.4% |
| Nov 2025 | $0.05 | $0.06 | +20.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Oct 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2026 | −$0.12 | — | — | $29.5M | — | — | — |
| Nov 6, 2026 | −$0.15 | — | — | $28.4M | — | — | — |
| Aug 7, 2026 | −$0.06 | −$0.12 | −111.8% | $26.5M | $29.1M | +9.9% | +4.2% |
| May 7, 2026 | −$0.06 | −$0.05 | +16.7% | $31.6M | $22.5M | −28.8% | −12.1% |
| Mar 12, 2026 | $0.06 | −$0.02 | −133.4% | $35.4M | $37.2M | +5.0% | −6.2% |
| Nov 7, 2025 | $0.05 | $0.06 | +20.0% | $32.9M | $30.6M | −7.2% | −1.8% |
| Aug 11, 2025 | |||||||
| May 9, 2025 | |||||||
| Mar 17, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 28, 2024 | |||||||
| Oct 26, 2023 | |||||||
| Aug 14, 2023 | |||||||
| May 15, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Nov 23, 2022 | |||||||
| Aug 15, 2022 | |||||||
| May 9, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Nov 12, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 4, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 11, 2020 | |||||||
| Feb 20, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 1, 2019 | |||||||
| May 2, 2019 | |||||||
| Mar 8, 2019 | |||||||
| Nov 1, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 3, 2018 | |||||||
| Mar 19, 2018 | |||||||
| Nov 2, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 11, 2017 | |||||||
| Mar 8, 2017 | |||||||
| Nov 3, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 5, 2016 | |||||||
| Mar 9, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Jul 31, 2015 |